Catalyst
Slingshot members are tracking this event:
AstraZeneca (AZN) MYSTIC trial testing durvalumab and durva + treme for treatment of lung cancer, on track for overall survival endpoint data readout in 2H 2018
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AZN | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 27, 2017
Occurred Source:
https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-reports-initial-results-from-the-ongoing-mystic-trial-in-stage-iv-lung-cancer-27072017.html
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Durvalumab, Durva + Treme, Lung Cancer, Overall Survival, Mystic
